HSC-4
HSC-4 is an orally active anti-inflammatory agent and a derivative of Hederacoside C (HY-N0253). HSC-4 inhibits the secretion of IL-6. HSC-4 exerts protective effects in mouse models of systemic sepsis and acute lung injury. HSC-4 can be used for the research of acute lung injury and systemic sepsis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3109806-14-3
- Formule: C45H73NO11
- Masse moléculaire:804.06
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
IL-6 |
HSC-4 (3.9-125 μM; 24 h) exhibits low cytotoxicity in RAW264.7 macrophages, with cell viability remaining above 83% even at concentrations up to 125 μM[1].
HSC-4 (2.3-60 μM; 2 h pre-incubation) potently inhibits LPS-induced IL-6 secretion in RAW264.7 macrophages, with extremely significant inhibitory effects observed at all tested concentrations ranging from 2.3 μM to 60 μM[1].
HSC-4 (2.3-60 μM; 2 h pre-incubation) inhibits LPS-induced TNF-α secretion in RAW264.7 macrophages, with significant inhibitory effects observed at concentrations of 2.3 μM, 20 μM and 60 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW264.7 macrophages
-
Concentration:3.9 μM, 7.8 μM, 15.6 μM, 31.3 μM, 62.5 μM, 125 μM
-
Incubation Time:24 h
-
Result:Showed negligible cytotoxicity across all tested concentrations, with cell viability values of 102.2% at 3.9 μM, 95.3% at 7.8 μM, 99.5% at 15.6 μM, 96.5% at 31.3 μM, 84.4% at 62.5 μM, and 83.2% at 125 μM.
-
Cell Line:LPS-stimulated RAW264.7 macrophages
-
Concentration:2.3 μM, 6.7 μM, 20 μM, 60 μM
-
Incubation Time:2 h pre-incubation
-
Result:Strongly inhibited LPS-induced IL-6 secretion in a concentration-dependent manner, with IL-6 levels of 28.7 pg/mL at 2.3 μM, 21.0 pg/mL at 6.7 μM, 11.5 pg/mL at 20 μM, and 5.6 pg/mL at 60 μM (model group IL-6 level: 58.1 pg/mL).
Exhibited highly significant inhibition at all tested concentrations (***P < 0.001 vs model group).\nInhibited LPS-induced TNF-α secretion, with TNF-α levels of 23.3 pg/mL at 2.3 μM, 35.0 pg/mL at 6.7 μM, 27.1 pg/mL at 20 μM, and 29.4 pg/mL at 60 μM (model group TNF-α level: 55.1 pg/mL).
Exhibited significant inhibition at 2.3 μM (***P < 0.001 vs model group), 20 μM (**P < 0.01 vs model group), and 60 μM (**P < 0.01 vs model group).
HSC-4 (50 mg/kg; p.o.; single treatment immediately after LPS challenge) exerts significant protective effects against LPS-induced acute lung injury[1].
HSC-4 (100-400 mg/kg; p.o.; daily; for 5 consecutive days) causes no significant hepatotoxicity or nephrotoxicity in KM mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 6-8 weeks old, specific pathogen-free, systemic sepsis model via intraperitoneal LPS injection at 4 mg/kg)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.; two doses (1 h pre-LPS and 1 h post-LPS)
-
Result:Significantly reduced IL-6 levels in the liver, heart, intestine, and lung compared to the model group, with efficacy comparable to or superior to dexamethasone and Hederacoside C.
Markedly alleviated LPS-induced tissue damage, including inflammatory cell infiltration and structural disruption, with comparable or superior protective effects in lung tissue relative to the positive control.
-
Animal Model:BALB/c (male, specific pathogen-free, acute lung injury model via intranasal LPS instillation at 2.9 mg/mL, 50 μL)[1]
-
Dosage:50 mg/kg
-
Administration:p.o.; single dose immediately post-LPS challenge
-
Result:Significantly reduced lung tissue levels of IL-1β, TNF-α, and IL-6 at 2 hours post-administration, with stronger inhibitory activity than dexamethasone at this time point.
Exerted maximal anti-inflammatory effect at 4 hours, with activity slightly weaker than dexamethasone.
Showed gradually declining inhibitory activity by 8 hours post-administration.
Chemical Information
-
CAS No. 3109806-14-3
-
Masse moléculaire 804.06
-
Formule C45H73NO11
-
SMILES
O[C@H]1[C@]([H])(O[C@@H]2[C@@H](O)[C@@H](O)CO[C@]2(O[C@@H]3[C@@](C)(CO)[C@@](CC[C@]4(C)[C@]5([H])CC=C6[C@@]4(C)CC[C@]7(C(NCC8CC8)=O)[C@@]6([H])CC(C)(C)CC7)([H])[C@]5(C)CC3)[H])O[C@@H](C)[C@H](O)[C@H]1O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
HSC-4 Related Classifications
HY-184691 Related Classifications
Powered by Bioz